Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's Sentinel To Begin Expansion This Fall

Executive Summary

Contracts for up to $220m to develop three new Sentinel centers will be awarded in September.

You may also be interested in...



Sentinel Could Be Used For Pregnancy Safety Studies Under PDUFA VII

User fee program inflation adjustment also proposed to be changed to account for only PDUFA-related personnel.

PDUFA VII Talks Begin With Similar Goals For Industry, US FDA

Both sides want enhancements to deal with growth in cell and gene therapy, as well as work on regulatory decision tools and finance issues.

Sentinel Study Transparency: FDA Tells Sponsors To Watch Journals, Conferences, Its Website For Results

MaPP indicates limited circumstances when Office of Surveillance and Epidemiology will tell a sponsor about the release of Sentinel safety study results.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS125441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel